DHR
Wall Street’s Danaher obsession continues
Danaher just got another reminder that analysts still think the company has room to run. A fresh MarketBeat roundup says 21 brokerages now split into 18 buys and 3 holds, leaving DHR with a consensus rating of “Moderate Buy.”
The target price gap is doing the heavy lifting
The average 12-month price target sits at $246.50, while the stock has been hanging around $195. That’s a pretty chunky gap, and for investors it matters because analyst target changes can keep sentiment warm even when the stock isn’t exactly throwing a parade.
Not exactly unanimous, but still pretty friendly
This wasn’t one clean upgrade — it was more like a chorus of analysts slightly remixing their opinions:
- Leerink Partners lifted its target to $270 and kept an outperform call
- Goldman Sachs trimmed its target to $230 but stayed at buy
- TD Cowen cut its target to $245 and also stayed bullish
- Guggenheim went the other way and bumped its target to $275 with a buy rating
So yes, the number tweaks are all over the place. But the vibe is still very much “don’t panic, we still like the name.”
Why you should care
Analyst consensus doesn’t magically move a stock on its own, but it can help set the mood. For a big healthcare tools name like Danaher, a healthy target premium can act like a soft cushion under the shares — especially when the broader market is hunting for quality and defensiveness.
Big picture: Danaher’s not getting a blockbuster new catalyst here, just another vote of confidence from Wall Street. Still, if you own the stock, it’s nice when the sell-side keeps handing you a map that points higher instead of a shrug.